Ellab Acquires PharmaProcess

“This acquisition marks an exciting step in innovating and strengthening our support for life science companies in Italy,” said Alessandra Ferrari, Business Manager, Italy. “With the synergy of Ellab’s products – ranging from our thermal validation systems to environmental monitoring systems – and PharmaProcess expertise in advanced services for facility design and commissioning, we are now positioned to offer truly comprehensive, end-to-end solutions for the life science sector.”

Established in 2018, PharmaProcess has earned recognition in the life science sector for its specialized business units in:

• Pharmaceutical Engineering Consultancy
• Commissioning & Validation
• Quality & GxP Compliance
• Computer System Validation

With a dedicated team of 40 skilled professionals, PharmaProcess has become a trusted partner for prominent pharmaceutical companies, delivering high-quality, process-driven solutions and providing critical support for strategic development projects.

The acquisition of PharmaProcess enhances Ellab’s service portfolio in Italy and Switzerland, enabling the delivery of integrated solutions for clients in the pharmaceutical and biotech industries.

Ellab and PharmaProcess’s combined offering provides comprehensive support for life science companies, addressing every stage from process design to validation, calibration, and quality assurance.

“This partnership empowers PharmaProcess to move confidently into the future, working alongside Ellab to create a more resilient and sustainable foundation for our team, our customers, and our business,” said Marco Alberio, CEO of PharmaProcess. “It’s a transformational moment that strengthens our commitment to deliver excellence while unlocking new opportunities for innovation and growth. With Ellab’s shared vision and values, we’re ready to take our services to the next level, ensuring that our employees have the tools and support they need to thrive and succeed in a fast-changing industry. This isn’t just a strategic decision; it’s a commitment to shaping a brighter future for everyone who is part of the PharmaProcess history.”

The synergy between Ellab and PharmaProcess combines Ellab’s compliance solutions with PharmaProcess’ expertise in regulatory compliance and specialized consulting. Clients can expect several key benefits:

• Expanded Expertise and Services: PharmaProcess’ specialized services will complement Ellab’s offerings, enabling clients to access a comprehensive range of project management, quality assurance, and process validation solutions in the region.
• Increased Flexibility and Compliance: PharmaProcess’ adaptable approach to regulatory changes and innovative technologies, combined with Ellab’s ability to deliver cutting-edge solutions, means enhanced data integrity and electronic data management.
• One Partner for End-to-End Support: by integrating Ellab’s compliance solutions with PharmaProcess’ consulting expertise, clients will benefit from a trusted, end-to-end partner dedicated to supporting the lifecycle of their critical processes in the life science sector.

Ellab supports the life science industry in meeting compliance standards by providing comprehensive validation, monitoring, and calibration products and services that ensure product integrity and quality. Since its acquisition by Novo Holdings in 2023, Ellab has been scaling its reach and presence to meet the global needs of the life science sector, building on its expanding capabilities.